In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Aerovate Therapeutics (AVTE – Research Report), with a price target of $27.00. The company’s shares closed last Friday at $22.63.
According to TipRanks, Harrison is a 5-star analyst with an average return of 14.5% and a 54.03% success rate. Harrison covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Viridian Therapeutics, and CymaBay Therapeutics.
Aerovate Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $36.67.
See Insiders’ Hot Stocks on TipRanks >>
AVTE market cap is currently $626.1M and has a P/E ratio of -8.26.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerovate Therapeutics (AVTE) Company Description:
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.
Read More on AVTE:
- Aerovate Therapeutics initiated with an Overweight at Wells Fargo
- Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
- Aerovate completes enrollment for Phase 2b portion of IMPAHCT study
- Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
- Aerovate Therapeutics reports Q3 EPS (71c), consensus (69c)
